As global preventative health tech and bio-nutritional assets capture high investor evaluations across sovereign bourses, utilizing capital markets to scale enterprise equity stands as a key financial catalyst to secure transcontinental growth. Specialized dietary supplement formulator Orzax has completed a major corporate milestone, clearing regulatory thresholds to list its shares on the public exchange. According to the official weekly bulletin published by the Capital Markets Board (SPK), the corporation's prospectus has been formally approved. Directed by leading brokerage house İnfo Yatırım, the corporate listing registers as one of the year's most notable mid-cap financial placements within the tracking logs updated as of June 25, 2026.
Deconstructing the IPO Architecture: Capital Matrices and Valuation Ratios
The public floatation framework designed by the İnfo Yatırım investment syndicate maps across specific quantitative metrics and capital allocation variables:
IPO Offer Price: The issue price for the bookbuilding phase has been structured at 69 TL per share. The allocation will be finalized under the "Fixed-Price Bookbuilding" and "Best-Efforts Underwriting" systems.
Nominal Share Allocation Matrix: An aggregate 52,500,000 TL nominal value shares will be dispatched into public investment streams. The operational breakdown specifies that 31,500,000 TL nominal value will float via primary capital increases (direct liquidity injection to the balance sheet), while 21,000,000 TL nominal value will be routed through secondary block sales by existing shareholders.
Post-Money Capitalization & Free Float: Upon final clearing, the enterprise’s paid-in capital base will expand from 307,000,000 TL to 338,500,000 TL. The post-money free float ratio is projected at 15.51%.
Aggregate Public Offering Volume: Evaluating the unit offer price against the consolidated share block volume, the total transaction value of Orzax’s public listing is expected to reach 3,622,500,000 TL.
Corporate Governance and Scaling Technical Asset Production
By completing its listing process on Borsa Istanbul (BIST), Orzax intends to leverage its freshly acquired working capital to support production capacity expansions, lock in continuous raw biomass procurement lines, harden international cross-border sales channels, and fund clinical R&D laboratory setups. The strategic pivot aims to align the company's internal operations with peak global compliance and auditing criteria.
The definitive calendar regulating institutional bookbuilding dates, final syndicate board configurations, and legal disclosure briefs will be declassified via official channels handled by İnfo Yatırım, Orzax, and the Public Disclosure Platform (KAP).
